Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anastrozole.

Jack Cuzick1

  • 1Wolfson Institute of Preventive Medicine, St. Bartholomew's Medical School, London, UK. Jack.Cuzick@cancer.org.uk

Drugs of Today (Barcelona, Spain : 1998)
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Anastrozole, an aromatase inhibitor, shows superior efficacy and tolerability over tamoxifen for estrogen receptor-positive breast cancer in both adjuvant and advanced settings. It is a recommended alternative first-line therapy for postmenopausal women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Quality and Suitability of Self-Collected Vaginal and Urine Samples for Human Papillomavirus Testing: A Prospective Matched Study.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Interventions for patients with prostate cancer on active surveillance: a narrative review.

BJU international·2025
Same author

Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.

British journal of cancer·2025
Same author

Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States.

Journal of the National Cancer Institute·2024
Same author

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.

JAMA·2024
Same author

A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention Trial.

Nutrients·2024
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Aromatase inhibitors (anastrozole, letrozole, exemestane) demonstrate greater efficacy than tamoxifen for estrogen receptor-positive breast cancer.
  • Tamoxifen is the established standard adjuvant treatment.

Purpose of the Study:

  • To review the mechanism of action and clinical trials of anastrozole.
  • To evaluate anastrozole's role in adjuvant and advanced settings for breast cancer.

Main Methods:

  • Review of recent clinical trials involving anastrozole.
  • Comparison of anastrozole with tamoxifen and megestrol acetate.

Main Results:

  • Anastrozole is more effective than tamoxifen in adjuvant and first-line advanced settings.
  • Anastrozole offers improved survival and side-effect profile compared to megestrol acetate in second-line treatment.

Related Experiment Videos

  • Anastrozole significantly prolongs disease-free survival and improves tolerability versus tamoxifen in the adjuvant setting.

    • Conclusions:

    • Anastrozole is a highly effective treatment option for estrogen receptor-positive breast cancer.
    • Anastrozole should be considered a first-line therapy alternative to tamoxifen in postmenopausal women with advanced disease.
    • Anastrozole demonstrates significant benefits in both adjuvant and advanced breast cancer treatment.